Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker
for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a …
for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a …
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells
…, I Anagnostopoulos, G Muehlinghaus, M Chatterjee… - Blood, 2004 - ashpublications.org
Notch receptors expressed on hematopoietic stem cells interact with their ligands on bone
marrow stromal cells and thereby control cell fate decisions and survival. We recently …
marrow stromal cells and thereby control cell fate decisions and survival. We recently …
[HTML][HTML] The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple …
M Chatterjee, M Andrulis, T Stühmer, E Müller… - …, 2013 - ncbi.nlm.nih.gov
Despite therapeutic advances multiple myeloma remains largely incurable, and novel
therapeutic concepts are needed. The Hsp90-chaperone is a reasonable therapeutic target, …
therapeutic concepts are needed. The Hsp90-chaperone is a reasonable therapeutic target, …
The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma
M Chatterjee, C Rancso, T Stühmer… - Blood, The Journal …, 2008 - ashpublications.org
Current knowledge about molecular mechanisms underlying disease progression and drug
resistance in multiple myeloma (MM) is still limited. Here, we analyzed the potential …
resistance in multiple myeloma (MM) is still limited. Here, we analyzed the potential …
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
T Stühmer, M Chatterjee, M Hildebrandt, P Herrmann… - Blood, 2005 - ashpublications.org
Mutation of p53 is a rare event in multiple myeloma, but it is unknown if p53 signaling is
functional in myeloma cells, and if targeted nongenotoxic activation of the p53 pathway is …
functional in myeloma cells, and if targeted nongenotoxic activation of the p53 pathway is …
STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival
M Chatterjee, S Jain, T Stühmer, M Andrulis… - Blood, 2007 - ashpublications.org
The combined blockade of the IL-6R/STAT3 and the MAPK signaling pathways has been
shown to inhibit bone marrow microenvironment (BMM)–mediated survival of multiple …
shown to inhibit bone marrow microenvironment (BMM)–mediated survival of multiple …
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow …
M Chatterjee, T Stühmer, P Herrmann, K Bommert… - Blood, 2004 - ashpublications.org
The interleukin-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3)
pathway contributes to the pathogenesis of multiple myeloma (MM) and protects MM cells …
pathway contributes to the pathogenesis of multiple myeloma (MM) and protects MM cells …
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
…, B Deschler-Baier, M Chatterjee… - …, 2021 - Future Medicine
Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell
engager (BiTE ® ) immune therapy mediating T-cell killing of tumor cells in patients with …
engager (BiTE ® ) immune therapy mediating T-cell killing of tumor cells in patients with …
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
…, A Garitano-Trojaola, S Fink, E Leich, M Chatterjee… - Leukemia, 2019 - nature.com
Despite an increasing number of approved therapies, multiple myeloma (MM) remains an
incurable disease and only a small number of patients achieve prolonged disease control. …
incurable disease and only a small number of patients achieve prolonged disease control. …
[HTML][HTML] Phase I study of the heparanase inhibitor roneparstat: An innovative approach for ultiple myeloma therapy
M Galli, M Chatterjee, M Grasso, G Specchia… - …, 2018 - ncbi.nlm.nih.gov
Reproducible plasma levels of roneparstat were measurable in cycle 1 at the two highest
dose levels, as shown in Online Supplementary Figure S1, which depicts plasma …
dose levels, as shown in Online Supplementary Figure S1, which depicts plasma …